Metadatos
Mostrar el registro completo del ítemCompartir este ítem
Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study.
Idioma
EN
Article de revue
Este ítem está publicado en
Molecular Biology Reports. 2022-03-01, vol. 49, n° 3, p. 2321-2324
Resumen en inglés
Numerous studies demonstrate parallels between CVD, type 2 diabetes mellitus (T2DM) and COVID-19 pathology, which accentuate pre-existing complications in patients infected with COVID-19 and potentially exacerbate the infection ...Leer más >
Numerous studies demonstrate parallels between CVD, type 2 diabetes mellitus (T2DM) and COVID-19 pathology, which accentuate pre-existing complications in patients infected with COVID-19 and potentially exacerbate the infection course. Antidiabetic drugs such as sodium-glucose transporter-2 (SGLT-2) inhibitors have garnered substantial attention recently due to their efficacy in reducing the severity of cardiorenal disease. The effect of SGLT-2 inhibitors in patients with COVID-19 remains unclear particularly since SGLT-2 inhibitors contribute to altering the RAAS cascade activity, which includes ACE-2, the major cell entry receptor for SARS-CoV2. A study, DARE-19, was carried out to unveil the effects of SGLT-2 inhibitor treatment on comorbid disease complications and concomitant COVID-19 outcomes and demonstrated no statistical significance. However, the need for further studies is essential to provide conclusive clinical findings.< Leer menos
Palabras clave en inglés
Angiotensin-Converting Enzyme 2
Benzhydryl Compounds
COVID-19
Clinical Trials
Phase III as Topic
Double-Blind Method
Drug Repositioning
Glucosides
Heart Diseases
Humans
Kidney Diseases
Mitochondria
Multicenter Studies as Topic
Oxidative Stress
Randomized Controlled Trials as Topic
Receptors
Virus
Renin-Angiotensin System
Respiratory Insufficiency
SARS-CoV-2
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
Centros de investigación